Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of ZW25 in Combination with Palbociclib Plus Fulvestrant
2019-002956-18Phase 2Active
- Sponsor
- Zymeworks Inc.
- Start
- Jan 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of zanidatamab in breast cancer, sponsored by Zymeworks Inc. Primary endpoint: Primary endpoint Part 1. Started Jan 2020; status: active.
02
Drugs
zanidatamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002956-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002956-18.